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Pharmaceutical applications of bioactive peptidesMK Danquah1,2*,D Agyei2
Abstract
Introduction
There is a mounting interest in the 
therapeutic potential of bioactive 
peptides which collectively present a 
cornucopia of bioactivities for 
exploitation in vivo. Bioactive peptides 
trigger certain functionalities such as 
antioxidative, antimicrobial, antihyper-
tensive, cytomodulatory and immuno-
modulatory activities in the living body 
system. With research and developm-
ent, there exists an opportunity to 
effectively harness these functionali-
ties for the treatment, prevention and 
mitigation of different medical cond-
itions. This critical review discusses 
some potential therapeutic applic-
ations of bioactive peptides in the light 
of advances in general bio-
pharmaceutical production based on 
proteomics and genomics.
Conclusion
Bioactive peptides are ubiquitous 
biomolecules widely abundant and 
easily obtained from food proteins and 
there is no limit to how many can be 
obtained froma single food protein.
Introduction
An ancient Chinese saying states 
that Medicine and food have a co-
mmon origin1. Centuries of resear-ch has confirmed and enhanced our understanding of the intimate link 
between nutrition and health. Asser-tions about the ability of foods and its components to enhance the ove-rall quality of life continues to capt-
ivate us even today2. Research has uncovered several bioactive compo-nents from food derived macro-bio-molecules (such as lipids and proteins); however, protein deriv-ed biomolecules are the most di-verse and most studied. Within the human body, some protein hydrolys-ates have been shown to trigger cert-ain ‘hormone-like’ responses that offer health benefits  in vivo and/or in vitro, eith-er in the  intact for-m or as hydrolysates3. These protein hydrolysates, (bioactive peptides), are specific protein fragments with the ability to  impart a physiologi-cally measurable biological effect re-sulting in a positive impact on body 
functions/conditions, thus ultimately 
influencing health4–6. Some positive 
physiological responses of bioactive peptides are antioxidative, antimic-robial, antihypertensive, cytomodul-atory and immunomodulatory effects under in vivo and in vitro conditio-
ns3,5,7–9. These are observed in the major body systems such as the di-gestive, cardiovascular, nervous, musculoskeletal and immune syste-
ms6. Thus, bioactive peptides can play a significant role in the pharm-aceutical industry since the physiolo-
gical responses induced are the same as the targeted responses intended by small molecules and biologics. This critical review highlights diffe-rent therapeutic applications of bio-active peptides with recent findings in the field.
Peptides as active pharmaceutical 
ingredientsProteins and peptides play important roles in living body systems by co-
ntrolling and coordinating inter and intra-cellular communications and cellular function. From a nutrition-al perspective, peptides are
more bioavailable than proteins or 
free amino acids10. Further, peptides with low molecular weight have been 
known to be less allergenic than their 
native proteins, explaining why milk 
protein hydrolysates are widely utilized in the formulation of hypoallergenic 
infant foods11. Additionally, as nature’s 
tool kit, the diverse physiological roles of peptidesmake them suitable candi-
dates for the development of thera-peutic agents12,13. There is a wide variety of physiological activities induced by 
bioactive peptides and these bioac-
tivities are determined by the type, 
number, sequence and properties of amino acids present in the peptide13,14. It is worth mentioning that whereas some proteins (such as lysozyme and 
α-lactalbumin) retain their bioactivi-ties even the unhydrolysed denatured 
state14, usually, the aforementioned 
bioactivities are latent until proteins 
are hydrolysed to release physiologi-
cally active peptides. Captured in 
Table 1 are some bioactive peptides and their bioactivities or areas of 
therapeutic applications. Bioactive peptides are therefore suitable candi-
dates for a new era of pharmaceutical 
products, especially with the height-ened concerns of side effects of small molecule drugs and the increased 
attention to fresher and ‘greener’ 
foods and nutraceuticals possessing 
health-preventing or health-promoting 
properties.
Changing trends
Research continues to uncover novel peptide sequences with potential appli-
cations in the prevention and mitiga-tion of ill health, the findings of which 
are of tremendous significance to the scientific community, pharmaceutical 
corporations and consumers alike. 
There is also a growing interest in the 
level of peptide therapeutics in the 
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pharmaceutical industry. It has been 
estimated that about 60 peptide drugs 
were approved and generated annual sales of around US$ 13 billion (about 
1.5% of all drug products) in 2010 alone. The numbers areincreasing 
significantly with a current continuous 
annual growth rate between 7.5% and 
10%10. Peptide-based therapeutics possess a long and secure future as a 
result of the following merits:
• There is an overall increasedacceptance of protein therapeu-tics by physicians, pharmaceutical
corporations and patients. For thepast three decades, in the United
States alone, the number of pep-tide new chemical entities (NCEs)
entering clinical study per yearper decade has increased by about
1300% (from 1.2 per year in the1970s to 16.8 per year so far in the 
2000s)15. This increased accept-ance has been partly attributed 
to the development of technologi-cal solutions to problems such as short half-life and delivery of the peptide molecules, previously 
encountered with the application of peptides as drugs16. Additionally, the risk of unforeseen side-reactions is unanticipated or at best reduced 
for food-derived peptide drug can-
didates. This is because most food 
proteins and peptides have a long 
history of use and aregenerally 
regarded as safe13. Also, the exist-ence of a structural relationship 
between peptide drug candidates and their safe physiologically active 
parent molecules substantially 
reduces the risk of unforeseen 
side-reactions. This is best demon-
strated in the fact that there is an 
over 20% probability of regulatory 
approval for peptide NCEs, a rate 
which is double to that of small 
molecules12.
•  Naturally, peptides play key
physiological roles in the body as peptide hormones, chemokines and 
cytokines. Since peptides are com-
posed of metabolically and aller-
genically tolerable amino acids, 
they are generally safe and non- 
toxic. Usually, any known side-
effects with peptide drugs have 
often been related to dosage or local 
reactions at the injection site12.
• Peptide-based therapeutics are
effective in addressing a wide array of medical disorders including indications in cancers and tumours, metabolic disorders, cardiovascu-lar health and infectious diseases. 
Peptides are structurally diverse, 
have wide spectrum of therapeutic action, low biodeposition in body 
Table 1 Some food protein hydrolysates and their therapeutic application
Protein source Microorganism  
or enzyme used
Amino acid 
sequence
Therapeutic application 
(bioactivity)*
Reference
Caprine milk Pepsin αs2-casein f(203–208) Antimicrobial;  
antihypertensive; 
antioxidant
Atanasova and 
Ivanova19
Bovine milk Lb. helveticus Ile-Pro-Pro; 
Val-Pro-Pro
Antihypertensive* Jäkälä and 
Vapaatalo38
Bovine milk Porcine intestinal 
enzymes
(Tyr-Pro-Phe- 
Pro-Gly-Pro-Ile- 
Pro-Asn-Ser-Leu)
β-casein 
f(60–70) 
Immunostimulatory, 
opioid agonist;  
ACE-inhibitory
Atanasova and  
Ivanova19; Meisel59
Bovine milk Enterococcus faecalis  
TH563 and Lb. delbrueckii 
ssp. bulgaricus LA2
Unidentified Immunostimulatory, 
ACE-inhibitory
Regazzo et al.60
Egg white Alcalase Arg-Val-Pro-Ser-Leu ACE-inhibitory Liu et al.58
Rice endosperm Neutrase Phe-Arg-Asp-Glu- 
His-Lys-Lys; and 
Lys-His-Asp-Arg- 
Gly-Asp-Glu-Phe
Antioxidative Zhang et al.61
Sweet potato 
juice
Thermoase PC10F, 
Protease S and  
Proleather FG-F
Ile-Thr-Pro; Ile-Ile- 
Pro; Gly-Gln-Tyr;  
Ser-Thr-Tyr-Gln-Thr
ACE-inhibitory Ishiguro et al.62
Lb., Lactobacillus; ACE, angiotensin converting enzyme.
*Meta-analyses of clinical studies.
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tissues and high biospecificity to 
targets13.
•
Apart from their use as active
ingredients, peptides also have the ability to be used as excipientsin drug formulations for modifica-
tion of biological activity, targeted
delivery or transport across cellu-lar membranes.
Discussion
The authors have referenced some of 
their own studies in this review. 
The protocols of these studies have 
been approved by the relevant ethics 
committees related to the institution 
in which they were performed.
Therapeutic applications of 
bioactive peptidesA considerably huge amount of 
scien-tific research data exists to 
demonstrate the therapeutic 
potential of bioactive peptides, 
some of which are human studies. Some of the physiological  
effects of peptides are shown in Table 
1 and others discussed briefly below.
Antimicrobial peptides
Several peptides have been identified as having antimicrobial properties. Like 
innate host defence peptides in multi-cellular organisms, these peptides are 
relatively short (between 10 and 50 amino acid residues), hydrophobic and 
cationic13,17,18. Natural compounds with 
antimicrobial activities act in diverse mechanisms; however, most antimi-
crobial bioactive peptidesact either 
by penetrating and disrupting micro-bial membrane integrity or by trans-locating across the membrane and acting on internal targets17,18. Antimi-
crobial peptides have been identified 
from many sources, especially from milk protein hydrolysates. Recently, a very potent antimicrobial peptide has been identified and obtained from 
cleavage of milk whey proteins such as 
lactoferrin19. Lactoferrin has attracted much interest in recent years. It is a potent antimicrobial agent against 
several enveloped and naked viruses such as rotavirus, enterovirus and 
adenovirus20. Further, tryptichydro-
lysate fractions of β-lactoglobulin whey 
proteins have been demonstrated as 
potent inhibitors of Listeria monocy-
togenes and Staphylococcus aureus. 
Two anionic peptides (Ile-Asp-Ala-Leu-
Asn-Glu-Asn-Lys and Thr-Pro-Glu-
Val-Asp-Asp-Glu-Ala-Leu-Glu-Lys) 
exhibited antimicrobial activity against the proliferation of Listeria and Staph-
ylococcus21. In another recent study, 
a randomized, controlled and blind 
study was performed on 60 human subjects to investigate whether and 
how consumption of goat milk cheese 
affects Helicobacter pylori activity in 
the stomach of these infected persons. 
The findings indicated that although the consumption of goat and cow milk (as cheese) did not reduce the 
activity of H. pylori in the stomach of 
infected persons, both cheeses helped 
improve subjects’ overall gastro- 
intestinal well-being22.
Conclusively, antimicrobial peptides 
are effective against a wide range of 
microbial hosts, including Gram- 
negative and Gram-positive bacteria, fungi, viruses and parasites. As such, not only are theypotential natural bio-
preservatives but are also effective in combating the rapidly increasing inci-dence of multidrug-resistant infections 
Figure 1: Alternative routes of production of bioactive peptides.
%LRDFWLYHSHSWLGHV)RRGSURFHVVLQJ8VHRIELRFDWDO\VW 0LFURELDO IHUPHQWDWLRQRI SURWHLQV6ROYHQWH[WUDFWLRQ 3HSWLGH V\QWKHVLVIURP DPLQRDFLGV ([SUHVVLRQLQ KRVWFHOOVYLD U'1$)RRGSURWHLQV 
Production and therapeutic 
applications of bioactive peptides
Broadly, biologically active peptides 
are obtained via four approaches: 
‘up-down degradation’, ‘whole expr-
ession’, ‘bottom-up’ construction or 
‘whole extraction’ (respectively, pat-
hways 1–4 of Figure 1). However, for 
the purpose of this review, a distinct-
ion has been made between the ter-
ms ‘bioactive peptides’ and other th-
erapeutic peptides. The term ‘bioact-
ive peptides’ has been confined to fo-
od protein-derived peptides which t-
rigger physiological biological activi-
ties in living body systems, to the ex-
clusion of chemically synthesied or 
whole isolated therapeutic peptides.
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whilst acting as alternate strategies 
to replace conventional antibiotics in 
controlling bacterial infections.
Anticancer peptidesAntitumour and anticancer drugs top the number of drug candidates being 
developed by pharmaceutical compa-nies since human cancer is one of the most important causes of death in the 
many developed countries. Although oncology research is well advanced and has enhanced our understanding of cancers, the therapeutic opportuni-ties are still limited owing to the dif-ficulty in selective targeting of cancer cells leaving healthy ones. Effective cancer therapies can utilize biomole-cules that target tumour-associated antigens expressed on cancer cells and directly modulate the prolifera-tion and survival of these cancerous 
cells23. Several anticancer peptides 
have been identified in a range of 
food protein hydrolysates. For example, 
recently, a novel anticancer peptide 
was identified via pepsin hydrolysates of proteins from the shellfish Mytilus-
coruscus. The hydrolysates were puri-fied and the peptide (with sequence identified as Ala-Phe-Asn-Ile-His-Asn-
Arg-Asn-Leu-Leu) effectively induced cell death on prostate, breast and lung cancer cells but not on normal 
liver cells24. Further, antioxidant and anticancer peptides rich in tyrosine, 
lysine, arginine, phenylalanine and histidine have been obtained via alcalase treatment of solitary tunicate 
(Styelaclava) proteins. Purification of the hydrolysateby gel-filtration gave 
two peptide fractions with antioxidant and anticancer activities each. The anti-cancer peptides significantly inhibited human stomach adenocarcinoma cell line (AGS), colorectal adenocarcinoma cell lines (DLD-1) and HeLa cells25.With their great potential in killing or 
controlling the growth and prolifera-tion of cancerous cells, bioactive pep-tides with anticancer properties have significant health-promoting effects that can be harnessed in the pharma-ceutical industry.
Antioxidative peptidesThe highly unstable and reactive nature 
offree radicals and reactive oxygen species (ROS) in the body results in cell damage and consequently leads 
to diseases such as hypertension, car-
diovascular, cancer, diabetes mellitus, and neurodegenerative and inflamma-
tory diseases26. Antioxidants protect the body by scavenging free radicals and ROS and also inhibiting lipid per-
oxidation reactions, thus preventing 
oxidative damage. Several studies have established the antioxidant properties of some peptides derived from differ-ent protein sources13,14,27–33. A very 
potent antioxidant has been identified 
from hoki frame protein hydrolysates 
by the use of pepsin, and this peptide (with the sequence identified as Glu-
Ser-Thr-Val-Pro-Glu-Arg-Thr-His-Pro-
Ala-Cys-Pro-Asp-Phe-Asn) exhibited 
lipid peroxidation inhibition levels 
higher than that of α-tocopherol, a well-
known antioxidant used as a positive 
control. The peptide also effectively quenched different sources of free 
radicals, including 1,1-diphenyl-2- 
pycryl-hydrazyl, hydroxyl, peroxyl and 
superoxide radicals; as well as decreased 
t-butyl hydroperoxide-induced cyto-
toxicity on human embryonic lung 
fibroblasts, whilst protecting free-
radical-induced DNA damage28. Anti-
oxidant peptides have also been identified and purified from sweet 
potato protein hydrolysates prepared 
from Alcalase. The peptides obtained 
were rich in hydrophobic amino acids and also contained high amounts of the antioxidant amino acids His, Met, 
Cys, Tyr and Phe. The peptides had 
protective effects against DNA dam-age through scavenging of hydroxyl 
radicals and Fe2+chelation34. Other anti-
oxidant peptides have been obtained via trypsin hydrolysates of Tilapia 
frame proteins. The antioxidant pep-tides were identified as Asp-Cys-Gly-
Tyr and Asn-Tyr-Asp-Glu-Tyr and had high hydroxyl radical scavenging 
activities26. Reference is made to 
Chalamaiah et al.35 and citations 
there in for comprehensive analyses 
of antioxidant peptides derived from 
food protein hydrolysates.
Antihypertensive peptides
Antihypertensive peptides are the most 
widely studied of all the bioactivities induced by food protein hydrolysates5. 
Angiotensin I-converting enzyme 
(ACE, peptidyldi-peptide hydrolase, EC 
3.4.15.1) is a key enzyme in the renin–
angiotensin system. This enzyme 
regulates extracellular fluid volume 
and arterial vasoconstriction either by 
converting angiotensin I to the vaso-
constrictor angiotensin II or by inacti-
vating the vasodilator bradykinin. Inhibition of ACE therefore results in a decrease in blood pressure, helping 
to control hypertension. The world-wide statistics of hypertension has 
shown that in 2000 the estimated 
total number of adults with hyperten-sion was 972 million and the number of adults with hypertension is predicted 
to increase by about 60% to a total of 
1.56 billion in 202536. Hypertension is 
therefore a global high-priority public-health challenge requiring urgent 
attention with prevention, detection, 
treatment and control. Although sev-
eral potent synthetic peptides are in use for the clinical treatment of hyper-
tension and heart failure, they are 
costly and are attended with numer-ous obnoxious side effects37. Antihy-
pertensive bioactive peptides are a suitable alternative since they are rela-
tively cheaper to produce with none 
or less attendant side effects13,14. Most of the antihypertensive peptides are 
usually short peptides and have a pro-line residue at the carboxyl terminal end. Proline residues help the pep-
tide to resist enzymatic degradation 
enroute the gastrointestinal carnal3. For 
example, the well-known antihyperten-
sive peptides are the lactotri peptides 
isoleucine-proline-proline (Ile-Pro-
Pro) and valine-proline-proline (Val-
Pro-Pro) which were obtained from sour milk5,38. Clinical trial studies 
have demonstrated that these two tripeptides affect health positively by 
reducing both systolic and diastolic 
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blood pressure in hypertensive 
patients39. Some new and potent anti-
hypertensive peptides have been iso-
lated from many plant food proteins. 
For example, a valine-and tryptophan-rich peptide with high in vivo anti- 
angiotensin converting enzyme (anti-
ACE) activity was identified and purified 
from alfalfa white protein concentrate 
hydrolysate40. Further, four potent ACE 
inhibitory peptides (Ile-Tyr, Arg-Ile-Tyr, 
Val-Trp and Val-Trp-Ile-Ser), have been 
isolated from subtilisin digest of rape-seed protein. All isolated peptides low-
ered blood pressure of spontaneously 
hypertensive rats following oral admin-
istration with maximum effect observed 
between 2 and 4 h41. These and the other antihypertensive peptides appear 
promising for incorporation into func-tional foods and pharmaceutical lead drugs where they may be useful in the prevention and treatment of hyper-
tension. Antihypertensive peptides help regulate fluid and salt balance in 
mammals42.
Cytomodulatory and 
immunomodulatory peptidesThe progression of disease conditions such as HIV and cancer in immuno-
compromised individuals is very 
rapid if not controlled properly. A new approach to therapy and robust 
macromolecules that modulates the  immune system is therefore a major 
research endeavour. Cytomodulatory peptides are suitable biologically 
active macromolecules for the modu-lation of body immune cells. They 
modulate the viability (e.g. prolifera-tion, differentiation and apoptosis) of 
different cell types, and together with 
immunomodulatory peptides might help in the control of tumour devel-
opment42. Research has uncovered peptides from Mozzarella cheese 
waste whey and these peptides 
showed significant antiproliferative 
effect on CaCo
2
 cell lines43. In another 
study, cytomodulatory peptides were 
shown to inhibit cancer cell growth 
while stimulating the activity of 
immunocompetent cells and neonatal 
intestinal cells44. Immunomodulatory peptides, on the other hand, bolster immune cell functions, improve anti-
body synthesis and cytochrome regu-lations and also enhance mucosal immunity in the gastrointestinal sys-
tem42. Several peptides with immu-
nomodulatory properties have been 
isolated from milk proteins where 
they trigger either specific (lympho-
cyte activation and proliferation, anti-
bodyproduction, cytokine expression) and/or non-specific (functions of 
macrophages, granulocytes and natu-
ral killer cells) immune responses5,45–47.
Derma-pharmaceuticals from bioactive 
peptidesWith respect to skin care, proteins and peptides are important due to their 
role in modulating cell proliferation, cell migration, cell and tissue inflam-mation, angiogenesis and melanogen-
esis48. A greater majority of products used in the skin care industry are pharmaceutical compounds. As such, 
bioactive peptides have a great poten-tial for use as active cosmetic and dermo-pharmaceutical ingredients. 
Currently, many patents exist for  
dermatological products obtainable 
from bioactive peptides. For example,  peptides of sequence X-Thr-Thr-Lys-Y, 
wherein in the particular X is lysine and Y is serine, have been patented (US patent no. 6620419) as useful in stimulating healing, hydrating or in all skin treatments. They are especially 
active against the formation of wrin-kles and against all the consequences of skin ageing as well as for dry skin49. 
Another disclosed invention (US patent 
no. 8071555) is a tetrapeptide with the amino acid sequence Pro-Glu-Glu-X 
(where X can be either lysine or  isoleucine). This tetrapeptide, as an 
active ingredient in skin care products 
are effective in controlling inflamma-
tory skin disorders50.
Multifunctional peptides and peptides 
with other bioactivitiesInterestingly, some bioactive peptides have demonstrated multifunctional 
roles, triggering two or three bioac-
tivities. Most of the bioactive peptides 
shown in Table 1 are multifunctional peptides. Lactoferrin is a classic exam-ple of a multifunctional peptide exhibit-ing antibacterial, antifungal, antiviral, 
antiparasitic and antitumour activi-ties while accelerating immunomod-
ulatory properties20. Other examples include peptides obtainable from ovine 
α
s2
-casein f(203–208)because it exhib-
its antimicrobial activity, antihyper-
tensive and antioxidant activities19.
There are other useful bioactivities of peptides which have not been 
covered in detail in this report. Among them include peptides that influence nutritional status and dental health, hypocholesterolemic pep-
tides, antithrombotic peptides, antiul-
cerogenic peptides, opioid peptides 
andmineral-binding peptides10,29,42,43.
Challenges to peptide therapeutics 
and useful ‘-omic’ toolsThe feasibility of pharmacological ap-plication of bioactive peptides depends on overcoming some challenges, including reduced biostability of peptides, lack of oral bioavailability, 
potential and a propensity to aggre-
gate into intractable deposits. Moreo-
ver, the correct biodistribution of 
bioactive peptides once delivered is sometimes hampered as a result of 
proteolytic attack. Despite these chal-lenges, research is well advanced in 
overcoming most of these challenges. Chemical modification of peptide 
backbone has been used to increase the stability of peptides in biological fluids. This is achieved via techniques such as amidation, polymer conjuga-tion and the introduction of disulphide 
bonds51–54. Moreover, new delivery 
strategies employing nanotechnology 
have been shown not only to protect peptides from enzymatic degradation but also to improve bioactive peptide 
delivery to target tissues55,56. Computer-based tools such as proteomic and computational peptidomic studies are helpful in enhancing peptide therapeu-
tics research. They allow optimisation 
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in the production of bioactive peptides, help in conducting peptide searches, and also help enhance the understand-ing of interaction mechanisms between 
receptors and bioactive peptides57. These help simplify peptide production 
by utilising computational (in silico) skills to predict peptides that can be obtained from a known food protein-
before undertaking wet-laboratory 
synthesis. With this approach, selection of enzymes, proteins and hydro-
lysates, as well as study the secondary 
structure and physicochemical prop-erties of peptides obtained can all be done in silico. Examples of peptide 
Database programs are BIOPEP 
and PepBank whilst PeptideCutter 
and POPS are proteolysis 
prediction peptide systems57. 
Integration of proteomic with 
peptidomic methodologies in the 
production of bioactive peptide 
science will enhance the 
throughput and productivity.  
Conclusion
Bioactive peptides are ubiquitous biomolecules widely abundant and 
easily obtainable from food proteins. 
There is no limit therefore to the number of peptides that can be obtained from a single food protein.Each of these peptides may present unique structure and biofunctionalities that can be exploited in the pharma-ceutical industry. As research contin-ues to uncover technologies and means 
to overcome challenges to the use of peptide therapeutics, the prospects of 
food-derived bioactive peptides will 
likely fuel in the pharmaceutical indus-
try an exodus from small molecules and biologics to bioactive peptides.
References
1. Arai S, Morinaga Y, Yoshikawa T, IchiishiE, Kiso Y, Yamazaki M, et al. Recent trends in functional food science and the indus-try in Japan. Biosci Biotechnol Biochem. 
2002 Oct;66(10):2017–29.
2. Milner JA. Functional foods and health: a US perspective. Br J Nutr. 2002 Nov; 
88(Suppl. S2):S152–8.
3. Korhonen H. Milk-derived bioactive
peptides: from science to applications. 
J Funct Foods. 2009 Apr;1(2):177–87.
4. Kitts DD, Weiler K. Bioactive proteinsand peptides from food sources. Applica-tions of bioprocesses used in isolation and 
recovery. Curr Pharm Des. 2003;9(16): 
1309–23.
5. Korhonen H, Pihlanto A. Bioactive 
peptides: production and functionality. 
Int Dairy J. 2006;16(9):945–60.
6. Möller NP, Scholz-Ahrens KE, Roos N,
Schrezenmeir J. Bioactive peptides and 
proteins from foods: indication for health 
effects. Eur J Nutr. 2008 Jun;47(4):171–82.
7. Gibbs B. Production and characteriza-tion of bioactive peptides from soy hydro-
lysate and soy-fermented food. Food Res 
Int. 2004 Mar;37(2):123–31.
8. Hartmann R, Meisel H. Food-derived
peptides with biological activity: from 
research to food applications. Curr Opin 
Biotechnol. 2007 Apr;18(2):163–9.
9. Yang R, Zhang Z, Pei X, Han X, Wang J,
Wang L, et al. Immunomodulatory effects of marine oligopeptide preparation from 
Chum salmon (Oncorhynchus keta) in mice. 
Food Chem. 2009 Mar;113(2):464–70.
10. Hajirostamloo B. Bioactive componentin milk and dairy product. World Acad Sci 
Eng Technol. 2010;72:162–6.
11. Host A, Halken S. Hypoallergenic 
formulas – when, to whom and how long: 
after more than 15 years we know the right 
indication! Allergy. 2004 Aug;59(Suppl. 78): 
45–52.
12. Lax R. The future of peptide develop-ment in the pharmaceutical industry. Phar 
Manufacturing: Int Pept Rev. 2010. Retrieved 
10th December, 2012, from http://www.
polypeptide.com/assets/002/5188.pdf
13. Agyei D, Danquah MK. Industrial-scale manufacturing of pharmaceutical-
grade bioactive peptides. Biotechnol Adv. 
2011 May–Jun;29(3):272–7.
14. Agyei D, Danquah MK. Rethinking food-
derived bioactive peptides for antimicro-bial and immunomodulatory activities. 
Trends Food Sci Technol. 2012 Feb;23(2012): 
62–9.
15. Reichert J. Development trends for peptide therapeutics –annual report. 2010. 
Retrieved 19th December, 2012, from 
http://www.peptidetherapeutics.org/
PTF_report_summary_2010.pdf.
16. Saladin PM, Zhang BD, Reichert JM.
Current trends in the clinical development of peptide therapeutics. IDrugs 2009 Dec; 
12(12):779–84.
17. Hancock REW, Sahl H-G. Antimicrobialand host-defense peptides as new anti-
infective therapeutic strategies. Nat 
Biotechnol. 2006 Dec;24(12):1551–7.
18. Steinstraesser L, Kraneburg U, Jacobsen
F, Al-Benna S. Host defense peptides and their antimicrobial-immunomodulatory 
duality. Immunobiology. 2011 Mar;216(3): 
322–33.
19. Atanasova J, IvanovaI. Antibacterialpeptides from goat and sheep milk pro-
teins. Biotechnol Biotechnol Equip. 2010 
May;24(2):1799–803.
20. Kanwar JR, Kanwar RK, Sun X, Punj V,Matta H, Morley SM, et al. Molecular and 
biotechnological advances in milk pro-
teins in relation to human health. Curr 
Protein Pept Sci. 2009 Aug;10(4):308–38.
21. Demers Mathieu V, Gauthier S, Britten M, Fliss I, Robitaille G, Jean J. Antibacterial 
activity of peptides extracted from tryptic 
hydrolyzate of whey protein by nanofiltra-
tion. Int Dairy J. 2013 Feb;28(2):94–101.
22. de Vrese M, Kristen H, Laue C,
Schrezenmeir J. Effects of goat cheese on 
Helicobacter pylori activity and gastroin-
testinal complaints. Int Dairy J. 2012 Dec; 
27(1–2):65–70.
23. Noguchi T, Kato T, Wang L, Maeda Y,
Ikeda H, Sato E, et al. Intracellular tumor-
associated antigens represent effective 
targets for passive immunotherapy. Cancer 
Res. 2012 Apr;72(7):1672–82.
24. Kim EK, Joung HJ, Kim YS, Hwang JW,Ahn CB, Jeon YJ, et al. Purification of a novel 
anticancer peptide from enzymatic hydro-
lysate of Mytilus coruscus. J Microbiol 
Biotechnol. 2012 Oct;22(10):1381–7.
25. Jumeri, KimS. Antioxidant and anti-cancer activities of enzymatic hydro-
lysates of solitary tunicate (Styela clava). 
Food Sci Biotechnol. 2011 Aug;20(4): 
1075–85.
26. Fan J, He J, Zhuang Y, Sun L. Purifica-tion and identification of antioxidant pep-tides from enzymatic hydrolysates of tilapia 
(Oreochromis niloticus) frame protein. 
Molecules. 2012;17(11):12836–50.
27. Kitts D. Antioxidant properties ofcaseinphospho peptides. Trends Food Sci 
Technol. 2005 Dec;16(12):549–54.
28. Kim S-Y, Je J-Y, Kim SK. Purificationand characterization of antioxidant pep-tide from hoki (Johnius belengerii) frame 
Page 7 of 7
Critical review
Licensee OA Publishing London 2012. Creative Commons Attribution License (CC-BY)
Co
m
pe
tin
g 
in
te
re
st
s:
 n
on
e 
de
cl
ar
ed
. C
on
fli
ct
 o
f i
nt
er
es
ts
: n
on
e 
de
cl
ar
ed
. 
A
ll 
au
th
or
s 
co
nt
rib
ut
ed
 to
 th
e 
co
nc
ep
tio
n,
 d
es
ig
n,
 a
nd
 p
re
pa
ra
tio
n 
of
 th
e 
m
an
us
cr
ip
t,
 a
s 
w
el
l a
s 
re
ad
 a
nd
 a
pp
ro
ve
d 
th
e 
fin
al
 m
an
us
cr
ip
t.
A
ll 
au
th
or
s 
ab
id
e 
by
 th
e 
A
ss
oc
ia
tio
n 
fo
r M
ed
ic
al
 E
th
ic
s 
(A
M
E)
 e
th
ic
al
 ru
le
s 
of
 d
is
cl
os
ur
e.
For cit ation purposes:  Danquah MK, Agyei D. Pharmaceutical applications of bioactive peptides. OA Biotechnology 
2012 Dec 29;1(2):5.
protein by gastrointestinal digestion. J Nutr 
Biochem. 2007 Jan;18(1):31–8.
29. Erdmann K, Cheung BWY, Schröder H. The possible roles of food-derived bioac-
tive peptides in reducing the risk of car-
diovascular disease. J Nutr Biochem. 2008 
Oct;19(10):643–54.
30. Wu J-H, Wang Z, Xu S-Y. Enzymatic
production of bioactive peptides from sericin recovered from silk industry waste 
water. Process Biochem. 2008 May;43(5): 
480–7.
31. Sheih IC, Wu TK, Fang TJ. Antioxidant
properties of a new antioxidative peptide 
from algae protein waste hydrolysate in 
different oxidation systems. Bioresour 
Technol. 2009 Jul;100(13):3419–25.
32. Vercruysse L, Smagghe G, Beckers T,
Van Camp J. Antioxidative and ACE inhibi-
tory activities in enzymatic hydrolysates of the cotton leafworm, Spodoptera littoralis. 
Food Chem. 2009 May;114(1):38–43.
33. Huang W, Deng Q, Xie B, Shi J, HuangFH, Tian B, et al. Purification and charac-
terization of an antioxidant protein from 
Ginkgo biloba seeds. Food Res Int. 2010 
Jan;43(1):86–94.
34. Zhang M, Mu T-H, Sun M-J. Sweet
potato protein hydrolysates: antioxidant 
activity and protective effects on oxidative 
DNA damage. Int J Food Sci Technol. 2012 
Nov;47(11):2304–10.
35. Chalamaiah M, Kumar BD, Hemalatha
R, Jyothirmayi T. Fish protein hydrolysates: 
proximate composition, amino acid com-position, antioxidant activities and applica-
tions: a review. Food Chem. 2012 Dec; 
135(4):3020–38.
36. Kearney PM, Whelton M, Reynolds K,Muntner P, Whelton PK, He J. Global bur-
den of hypertension: analysis of worldwide 
data. Lancet. 2005 Jan;365(9455):217–23.
37. Roy F, BoyeJ I, Simpson BK. Bioactive
proteins and peptides in pulse crops: pea, 
chickpea and lentil. Food Res Int. 2010 
Mar;43(2):432–42.
38. Jäkälä P, Vapaatalo H. Antihyperten-
sive peptides from milk proteins. Pharma-
ceuticals. 2010;3(1):251–72.
39. Marques C, Amorim M, Pereira JO,Pintado ME, Moura D, Calhau C, et al. Bioac-
tive peptides – are there more antihyper-
tensive mechanisms beyond ACE inhibition? 
Curr Pharm Des. 2012;18(30):4706–13.
40. Boudesocque L, Kapel R, Paris C, 
Dhulster P, Marc I, Renault JH. Concentra-tion and selective fractionation of an antihy-
pertensive peptide from an alfalfa white 
proteins hydrolysate by mixed ion-exchange 
centrifugal partition chromatography. J 
Chromatogr B. 2012 Sep;905(0):23–30.
41. Marczak ED, Usui H, Fujita H, Yang Y,
Yokoo M, Lipkowski AW, et al. New antihy-
pertensive peptides isolated from rape-
seed. Peptides. 2003 Jun;24(6):791–8.
42. Abd El-Salam MH, El Shibiny S.
Bioactive peptides of buffalo, camel, goat, sheep, mare, and yak milks and milk prod-
ucts. Food Rev Int. 2013 Jan;29(1):1–23.
43. De Simone C, Picariello G, Mamone G,Stiuso P, Dicitore A, Vanacore D, et al. 
Characterisation and cytomodulatory 
properties of peptides from Mozzarella di 
Bufala Campana cheese whey. J Pept Sci. 
2009 Mar;15(3):251–8.
44. Meisel H, FitzGerald RJ. Biofunctional
peptides from milk proteins: mineral binding and cytomodulatory effects. Curr 
Pharm Des. 2003;9(16):1289–95.
45. Meisel H. Multifunctional peptides 
encrypted in milk proteins. Bio Factors. 
2004;21(1–4):55–61.
46. Gauthier SF, Pouliot Y, Saint-Sauveur
D. Immunomodulatory peptides obtained 
by the enzymatic hydrolysis of whey pro-
teins. Int Dairy J. 2006;16(11):1315–23.
47. Huang, S-M, Chen K-N, Chen Y-P, Hong 
W-S, Chen M-J. Immunomodulatory prop-erties of the milk whey products obtained 
by enzymatic and microbial hydrolysis. 
Int J Food Sci Technol. 2010 May;45(5): 
1061–7.
48. Fields K, Falla TJ, Rodan K, Bush L. 
Bioactive peptides: signaling the future. 
J Cosmet Dermatol. 2009 Mar;8(1):8–13.
49. Lintner K. Cosmetic or dermophar-maceutical use of peptides for healing, 
hydrating and improving skin appearance during natural or induced ageing (helio-dermia, pollution). 2000. U.S. Patent. France, Sederma (Le Perray en Yvelines, FR) WO/ 
2000/015188.
50. Zhang L, Harris SM, Falla TJ. Protec-
tive skin care peptides. 2011. U.S. Patent. 
USA, Helix BioMedix Inc. (Bothell, MA) 
8071555:25.
51. Fowler SB, Poon S, Muff R, Chiti F, Dobson CM, Zurdo J, et al. Rational design of 
aggregation-resistant bioactive peptides: 
reengineering human calcitonin. Proc Natl 
Acad Sci USA. 2005 Jul;102(29):10105–10.
52. Chufán EE, De M, Eipper BA, Mains RE, Mario Amzel L. Amidation of bioactive 
peptides: the structure of the lyase do-main of the amidating enzyme. Structure 
2009 Jul;17(7):965–73.
53. Veronese FM, Pasut G, Drioli S, BonoraGM. Poly (ethylene glycol)-protein, pep-tide, and enzyme conjugates. LH Reddy, P 
Couvreur (editors), Macromolecular Anti-
cancer Therapeutics: Cancer Drug Discov-
ery and Development, 2010:pp265–88.
54. Knerr PJ, Tzekou A, Ricklin D, Qu H, Chen H, van der Donk WA, et al. Synthesis and activity of thioether-containing ana-logues of the complement inhibitor comp-
statin. ACS Chem Biol. 2011;6(7):753–60.
55. Ladewig K, Xu Z. Layered double hy-
droxide nanoparticles in gene and drug 
delivery. Expert Opin Drug Deliv. 2009 Sep; 
6(9):907–22.
56. Santo V, Gomes M, Mano JF, Reis RL. 
From nano- to macro-scale: nanotechnology 
approaches for spatially controlled deliv-ery of bioactive factors for bone and carti-lage engineering. Nanomedicine. 2012 Jul; 
7(7):1045–66.
57. Carrasco-Castilla J, Hernández-Álvarez A, Jiménez-Martínez C, Gutiérrez-López GF, 
Dávila-Ortiz G. Use of proteomics and peptidomics methods in food bioactive peptide science and engineering. Food 
Eng Rev. 2012 Dec;4(4):224–43.
58. Liu J, Yu Z, Zhao Z, Lin S, Wang E, Zhang Y, et al. Isolation and identification of angiotensin-converting enzyme inhibi-
tory peptides from egg white protein 
hydrolysates. Food Chem. 2010 Oct;122(4): 
1159–63.
59. Meisel H. Overview on milk protein-
derived peptides. Int Dairy J. 1998 May; 
8(5–6):363–73.
60. Regazzo D, Da Dalt L, Lombardi A,
Andrighetto C, Negro A, Gabai G. Fermented 
milks from Enterococcus faecalis TH563 and Lactobacillus delbrueckii subsp. bulg-
aricus LA2 manifest different degrees of 
ACE-inhibitory and immunomodulatory 
activities. Dairy Sci Technol. 2010 Jul–Aug; 
90(4):469–76.
61. Zhang J, Zhang H, Wang L, Guo X, WangX, Yao H. Isolation and identification of 
antioxidative peptides from rice endosperm 
protein enzymatic hydrolysate by consec-
utive chromatography and MALDI-TOF/
TOF MS/MS. Food Chem. 2010 Mar; 
119(1):226–34.
62. Ishiguro K, Sameshima Y, Kume T, Ikeda K, Matsumoto J, Yoshimoto M. Hypoten-
sive effect of a sweetpotato protein digest in spontaneously hypertensive rats and purification of angiotensin I-converting enzyme inhibitory peptides. Food Chem. 
2012 Apr;131(3):774–9.
